NEUROTERA: For the placing on the market of new therapeutic agents against ocular and cerebral comorbidities associated with paramyloidosis (Q2907213): Difference between revisions
Jump to navigation
Jump to search
(Changed label, description and/or aliases in de: Adding German translations) |
(Changed label, description and/or aliases in nl: Adding Dutch translations) |
||
| label / nl | label / nl | ||
NEUROTERA.: Voor het in de handel brengen van nieuwe therapeutische middelen tegen oculaire en hersencomorbiditeiten in verband met paramylloïdose | |||
Revision as of 12:37, 19 December 2021
Project Q2907213 in Portugal
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | NEUROTERA: For the placing on the market of new therapeutic agents against ocular and cerebral comorbidities associated with paramyloidosis |
Project Q2907213 in Portugal |
Statements
891,221.0 Euro
0 references
1,136,308.0 Euro
0 references
78.43 percent
0 references
16 August 2016
0 references
15 February 2020
0 references
BSIM THERAPEUTICS, S.A.
0 references
Q2988326 (Deleted Item)
0 references
Identifiers
POCI-01-0247-FEDER-003431
0 references